Japan Pricing Update: Trodelvy, Tepezza Win Usefulness Premiums, Awiqli Struggles

Multiple New Drugs Price-Listed In NHI

While Japan awarded relatively high premiums to several products newly listed for reimbursement, others were the subject of prolonged debate or are facing imminent cost-effectiveness assessment.

(Shutterstock)

More from Japan

More from Market Access